首页> 外文会议>Asia-Pacific Bioinformatics Conference >Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory
【24h】

Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory

机译:采用机器学习算法和拓扑图论对非小细胞肺癌的药物重新定位

获取原文

摘要

Background: Non-small cell lung cancer (NSCLC) is one of the leading causes of death globally, and research into NSCLC has been accumulating steadily over several years. Drug repositioning is the current trend in the pharmaceutical industry for identifying potential new uses for existing drugs and accelerating the development process of drugs, as well as reducing side effects.Results: This work integrates two approaches - machine learning algorithms and topological parameter-based classification - to develop a novel pipeline of drug repositioning to analyze four lung cancer microarray datasets, enriched biological processes,potential therapeutic drugs and targeted genes for NSCLC treatments. A total of 7 (8) and 11 (12) promising drugs (targeted genes) were discovered for treating early- and late-stage NSCLC, respectively. The effectiveness of these drugs is supported by the literature, experimentally determined in-vitro IC_(50) and clinical trials. This work provides better drug prediction accuracy than competitive research according to IC_(50) measurements.Conclusions: With the novel pipeline of drug repositioning, the discovery of enriched pathways and potential drugs related to NSCLC can provide insight into the key regulators of tumorigenesis and the treatment of NSCLC. Based on the verified effectiveness of the targeted drugs predicted by this pipeline, we suggest that our drug-finding pipeline is effective for repositioning drugs.
机译:背景:非小细胞肺癌(NSCLC)是全球致命的主要死因之一,研究NSCLC已经积累了几年。药物重新定位是制药行业的当前趋势,用于识别现有药物的潜在新用途,并加速药物的开发过程,以及减少副作用。结果:这项工作集成了两种方法 - 基于机器学习算法和基于拓扑参数的分类 - 开发一种新型药物重新定位管道,以分析四种肺癌微阵列数据集,富集的生物过程,潜在的治疗药物和用于NSCLC治疗的靶向基因。发现总共7(8)和11(12)个有希望的药物(靶向基因)分别用于治疗早期和晚期NSCLC。这些药物的有效性由文献支持,实验确定的体外IC_(50)和临床试验。根据IC_(50)测量,这项工作提供了比竞争性研究更好的药物预测精度。结论:随着药物重新定位的新型管道,富集的途径和与NSCLC相关的潜在药物的发现可以提供对肿瘤鉴定的关键调节因子和治疗NSCLC。根据本市管道预测的靶向药物的经过认证的效果,我们建议我们的药物发现管道对重新定位药物有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号